Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments principally to treat highly prevalent dermatology indications using its proprietary hypochlorous acid (HOCl) technology, which has shown immunomodulatory properties coupled with a potentially favourable safety profile. FY’17 highlights included entry of lead program PR022 a topical gel to treat Atopic Dermatitis into FDA Phase II study due to provide headline data in Q3’18.
03 May 2018
Atopic Dermatitis data the focus in 2018
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Atopic Dermatitis data the focus in 2018
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
03 May 2018 -
Author:
Emma Ulker -
Pages:
3
Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments principally to treat highly prevalent dermatology indications using its proprietary hypochlorous acid (HOCl) technology, which has shown immunomodulatory properties coupled with a potentially favourable safety profile. FY’17 highlights included entry of lead program PR022 a topical gel to treat Atopic Dermatitis into FDA Phase II study due to provide headline data in Q3’18.